Search results
Results from the WOW.Com Content Network
Rare AFP-secreting tumor types include carcinoma in a mixed Müllerian tumor. [14] The Sertoli-Leydig cell tumor, which itself is rare, rarely secretes AFP. [15] In Wilms tumor AFP is rarely elevated, but when it is elevated it may serve as a marker of disease progression or recurrence. [16]
Alpha-fetoprotein (AFP, α-fetoprotein; also sometimes called alpha-1-fetoprotein, alpha-fetoglobulin, or alpha fetal protein) is a protein [5] [6] that in humans is encoded by the AFP gene. [ 7 ] [ 8 ] The AFP gene is located on the q arm of chromosome 4 (4q13.3). [ 9 ]
Tumor marker Associated tumor types Alpha fetoprotein (AFP) germ cell tumor, hepatocellular carcinoma [8] CA15-3: breast cancer [9] CA27.29: breast cancer [10] CA19-9: Mainly pancreatic cancer, but also colorectal cancer and other types of gastrointestinal cancer. [11] CA-125
Usefulness of lens culinaris agglutinin A-reactive fraction of alpha-fetoprotein (AFP-L3) as a marker of distant metastasis from hepatocellular carcinoma. Yamashiki, N., et al., Oncology Reports, 6, 1229–1232, 1999. Relationship between lens culinaris agglutinin reactive alpha-fetoprotein and biological features of hepatocellular carcinoma.
One example of an oncofetal antigen is alpha-fetoprotein, which is produced by hepatocellular carcinoma and some germ cell tumors. Another example is carcinoembryonic antigen , which is elevated in people with colon cancer and other tumors.
Of special concern is the secretion of alpha-fetoprotein (AFP); under some circumstances, AFP can be used as a diagnostic marker specific for the presence of yolk sac cells within the teratoma. These cells can develop into a frankly malignant tumor known as yolk sac tumor or endodermal sinus tumor.
Pages in category "Tumor markers" ... AFP-L3; Alpha-fetoprotein; Alpha-methylacyl-CoA racemase; B. BRCA1; BRCA2; C. CA 15-3; CA 27-29; CA 242 (tumor marker) CA19-9 ...
In the United States, the American Association for the Study of Liver Diseases(AASLD) recommends ultrasound screenings every six months for people with cirrhosis, with or without measurement of blood levels of the tumor marker alpha-fetoprotein (AFP).